Extent of lymphadenectomy dictates adjuvant chemotherapy benefit in primarily resected esophageal squamous cell carcinoma: a multi-cohort validation
Das Ausmaß der Lymphadenektomie bestimmt den Nutzen der adjuvanten Chemotherapie bei primär reseziertem ösophagealem Plattenepithelkarzinom: Multi-Kohorten-Validierung
Frontiers in Oncology · 29.10.2026 · 16
DOI: 10.3389/fonc.2026.1920549 ↗Auf einen Blick
Bei ESCC nach primärer Resektion zeigte sich ein Nutzen der adjuvanten Chemotherapie abhängig von der Zahl entfernter Lymphknoten. Der Cut-off lag bei 21 Lymphknoten.
Fragestellung
Gibt es einen Lymphknoten-Entfernungsgrenzwert, der den Nutzen einer adjuvanten Chemotherapie nach primärer Resektion bei ESCC stratifiziert?
Methode
Retrospektive Multi-Kohorten-Studie mit SEER-Daten (n = 753) und chinesischem Einzelzentrum (n = 447); Cutpoint-Analyse mit X-tile, Cox-Nomogramm und 1:1-PSM.
Ergebnisse
21 Lymphknoten wurden als optimaler LND-Threshold bestimmt. Bei < 21 Lymphknoten brachte adjuvante Chemotherapie einen Überlebensvorteil (P = 0,048), bei ≥ 21 keinen weiteren Vorteil (P = 0,085).
Schlussfolgerung der Autor:innen
Eine Entfernung von ≥ 21 Lymphknoten war ein robuster anatomischer Biomarker und veränderte den postoperativen Therapieeffekt bei ESCC; bei suboptimaler LND war adjuvante Chemotherapie nötig, bei ≥ 21 Lymphknoten nicht.
Kernaussagen
- Optimaler LND-Threshold: 21 Lymphknoten
- < 21 Lymphknoten: Vorteil durch adjuvante Chemotherapie
- ≥ 21 Lymphknoten: kein zusätzlicher Überlebensvorteil
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 29.10.2026. Verfasst von Yicheng Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
While primary surgery remains a crucial treatment for resectable esophageal squamous cell carcinoma (ESCC), the uniform application of postoperative adjuvant chemotherapy for pathologically node-positive patients exposes many to severe systemic toxicity. This study hypothesizes the existence of a specific lymph node dissection (LND) threshold that stratifies the survival benefit of adjuvant chemotherapy and aims to define this cutpoint to enable safe therapeutic de-escalation.
Methods
We conducted a multi-cohort retrospective study using data from the Surveillance, Epidemiology, and End Results (SEER) database (n = 753, training cohort) and a Chinese single-center repository (n = 447, validation cohort) of patients with ESCC who underwent primary radical esophagectomy without radiotherapy. The optimal prognostic cutpoint for LND was mathematically determined using X-tile software. An interactive Cox proportional hazards nomogram incorporating an LND-by-chemotherapy interaction term was developed and validated. Subsequently, layer-specific 1:1 propensity score matching (PSM) was performed within separate surgical strata of the validation cohort to assess chemotherapy efficacy.
Results
X-tile analysis established 21 lymph nodes as the optimal LND threshold. Multivariable analysis confirmed that adequate LND (≥ 21 nodes) and adjuvant chemotherapy were independent protective prognostic factors. The interactive nomogram demonstrated good discrimination and calibration across both populations. Crucially, layer-specific PSM in the external validation cohort revealed divergent therapeutic responses dependent on surgical quality. For patients with suboptimal LND (< 21 nodes), adjuvant chemotherapy provided a significant survival benefit over surgery alone (P = 0.048). In contrast, for patients achieving an adequate LND (≥21 nodes), the addition of adjuvant chemotherapy yielded no further survival advantage (P = 0.085).
Conclusions
Achieving the removal of ≥ 21 lymph nodes serves as a robust anatomical biomarker that fundamentally alters the postoperative therapeutic landscape for ESCC. Patients with suboptimal LND require adjuvant chemotherapy to compensate for potential residual disease, whereas those achieving the 21-node clearance threshold derive no additional survival benefit from systemic interventions and can be safely exempted from cytotoxic over-treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fuzhou, Fujian, China.
- Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, Fujian, China.
- Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, Fujian, China.
- Clinical Research Center for Thoracic Tumors of Fujian Province, Fujian Medical University, Fuzhou, Fujian, China.
Zitieren
APA
Huang, Y., Lin, X., Lin, Y., & Han, Z. (2026). Extent of lymphadenectomy dictates adjuvant chemotherapy benefit in primarily resected esophageal squamous cell carcinoma: a multi-cohort validation. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1920549
Vancouver
Huang Y, Lin X, Lin Y, Han Z. Extent of lymphadenectomy dictates adjuvant chemotherapy benefit in primarily resected esophageal squamous cell carcinoma: a multi-cohort validation. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1920549
BibTeX
@article{Huang2026,
author = {Huang, Yicheng and Lin, Xuanhao and Lin, Yanhong and Han, Ziyang},
title = {Extent of lymphadenectomy dictates adjuvant chemotherapy benefit in primarily resected esophageal squamous cell carcinoma: a multi-cohort validation},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1920549}
}
EUVIMED